Copyright
©The Author(s) 2021.
World J Clin Cases. Dec 6, 2021; 9(34): 10549-10556
Published online Dec 6, 2021. doi: 10.12998/wjcc.v9.i34.10549
Published online Dec 6, 2021. doi: 10.12998/wjcc.v9.i34.10549
Table 4 Adverse events experienced by patients treated with vancomycin (only) or with vancomycin and teicoplanin, n (%)
| Group | Number of cases | Gastrointestinal reaction | Dizziness and headache | Vomiting and nausea | Total incidence |
| Study group | 43 | 2 (4.65) | 1 (2.33) | 2 (4.65) | 5 (11.63) |
| Control group | 43 | 0 (0.00) | 2 (4.65) | 1 (2.33) | 3 (6.98) |
| χ2 value | 0.551 | ||||
| P value | 0.458 |
- Citation: Wu W, Liu M, Geng JJ, Wang M. Teicoplanin combined with conventional vancomycin therapy for the treatment of pulmonary methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis infections. World J Clin Cases 2021; 9(34): 10549-10556
- URL: https://www.wjgnet.com/2307-8960/full/v9/i34/10549.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i34.10549